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Abstract
Background: The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast
cancer. AR is expressed in 60–80% of breast cancers, with higher prevalence among estrogen receptor-positive
(ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is
associated with improved survival for this subtype in epidemiologic studies. However, whether AR expression
modifies the efficacy of selective ER modulators or aromatase inhibitors for ER+ cancers remains unclear.
Methods: We evaluated the prognostic and predictive value of AR expression among 3021 postmenopausal ER+
breast cancer patients in the Breast International Group (BIG) trial 1–98. The BIG 1–98 study was a four-armed,
double-blind, phase III randomized clinical trial that compared 5 years of tamoxifen or letrozole monotherapy, or
sequences of 2 years and 3 years treatment with one drug and then the other. AR expression was measured by
immunohistochemistry and the percentage of AR-positive nuclei was quantified. The association between AR
expression and prognosis was evaluated using Cox proportional hazards models. Continuous AR-by-treatment
interactions were assessed using Subpopulation Treatment Effect Pattern Plots (STEPP).
Results: Eighty-two percent of patients had AR+ (≥ 1%) tumors. Patients with AR+ cancers were more likely to
have smaller, lower-grade tumors, with higher expression of ER and PR. AR expression was not associated with
breast cancer-free interval (BCFI) (415 events) over a median 8.0 years of follow-up (p = 0.12, log-rank test). In
multivariable-adjusted models, AR expression was not associated with BCFI (HR = 1.07, 95% CI 0.83–1.36, p = 0.60).
The letrozole versus tamoxifen monotherapy treatment effect did not significantly differ for AR+ tumors (HR = 0.63,
95% CI 0.44–0.75, p = 0.003) and AR− tumors (HR = 0.39, 95% CI 0.21–0.72, p = 0.002) (p-heterogeneity = 0.16). STEPP
analysis also suggested no heterogeneity of the treatment effect across the continuum of AR expression.
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Conclusions: AR expression was not associated with prognosis, nor was there heterogeneity of the letrozole versus
tamoxifen treatment effect by AR expression. These findings suggest that AR expression may not be an informative
biomarker for the selection of adjuvant endocrine therapy for postmenopausal women with ER+ breast cancers.
Trial registration: ClinicalTrials.gov, NCT00004205, Registered 27 January 2003—Retrospectively registered, https://
clinicaltrials.gov/ct2/show/study/NCT00004205.
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Background
Sex steroid hormone receptor signaling is vital in the de-
velopment and progression of breast cancers. The role
of the estrogen receptor (ER) in breast cancer has been
well elucidated, and estrogen blockade using selective es-
trogen receptor modulators (SERMs) and aromatase in-
hibitors is fundamental in breast cancer therapeutics [1,
2]. The androgen receptor (AR) is expressed in 60–80%
of breast tumors, though its prevalence is correlated
with tumor ER expression [3–7]. Approximately 90% of
ER+ breast cancers express AR, while only 20–30% of
ER− breast cancers are AR+.
Preclinical and clinical data support differential effects
of AR signaling in breast cancers, dependent on tumor
ER expression [8–10]. In ER− breast cancers, AR signal-
ing can drive tumor growth [11]; however, epidemiologic
studies have yielded inconsistent evidence regarding the
prognostic value of AR in this subtype [12]. In contrast,
AR signaling has been shown to antagonize cell prolifer-
ation in ER+ breast cancers in in vitro models [13]. This
may occur through competition between AR and ER for
binding sites at estrogen response elements or through
competition for transcriptional co-regulators [13].
Population-based studies support the hypothesis that AR
may antagonize the detrimental effects of ER signaling,
and have shown a consistent inverse association between
tumor AR expression and mortality among patients with
ER+ breast cancer [7, 12, 14].
The Breast International Group (BIG) trial 1–98 was a
phase III randomized clinical trial that evaluated letro-
zole (an aromatase inhibitor) versus tamoxifen (a SERM)
as an adjuvant therapy for early stage hormone
receptor-positive breast cancer among 8010 postmeno-
pausal women [15]. The initial and subsequent reports
found superior disease-free survival among those ran-
domized to 5 years of letrozole monotherapy compared
to those randomized to tamoxifen monotherapy [16, 17].
Secondary analyses found that the letrozole versus tam-
oxifen treatment effect was stronger for tumors with
high Ki67 expression, but the effect did not differ by
tumor progesterone receptor (PR) or human epidermal
growth factor 2 (HER2) expression [18–20].
There is conflicting evidence surrounding AR as a pre-
dictive marker of tamoxifen response, with prior studies
indicating that high AR expression is associated with im-
proved response and that a high AR:ER ratio is associated
with tamoxifen resistance [21, 22]. No studies to date have
evaluated AR as a predictor of response to letrozole. Given
the purported antagonistic effects of AR signaling in ER+
breast cancer, we postulate that the efficacy of letrozole
may be stronger in AR+/ER+ cancers. Blockade of testos-
terone conversion to estradiol may result in increased AR
signaling and subsequently inhibit tumor growth. Andro-
gen therapies were effective for the treatment of
hormone-responsive breast cancers and were commonly
administered prior to the introduction of tamoxifen [23,
24]. Additionally, cotreatment with bicalutamide, a non-
steroidal AR antagonist, eliminated the antiproliferative
effects of letrozole in MCF7 cells [25].
We leveraged the resources of the BIG 1–98 trial to
evaluate AR protein expression as a marker of prognosis
among postmenopausal women with early stage ER+
breast cancer. Additionally, we also assessed AR expres-
sion as a predictor of differential efficacy of letrozole
and tamoxifen adjuvant therapy in this population.
Methods
Study design
BIG 1–98 was an international, multicenter, phase III,
double-blind, four-arm randomized trial conducted
among postmenopausal women with early stage hor-
mone receptor-positive breast cancer. The design of the
trial has been described in detail previously [15–17].
From March 1998 to March 2000, participants were ran-
domized to receive 5 years of monotherapy with either
letrozole (2.5 mg/d) or tamoxifen (20 mg/d). Participants
enrolled between April 2000 and May 2003 were ran-
domized to either 5 years monotherapy with either letro-
zole or tamoxifen, 2 years of letrozole followed by
3 years of tamoxifen, or 2 years of tamoxifen followed by
3 years of letrozole. The primary efficacy analysis in-
cluded 8010 eligible participants and showed superiority
of letrozole therapy to tamoxifen therapy [16]. Following
publication of the primary efficacy analysis, participants
in the tamoxifen monotherapy arm were offered the op-
portunity to receive letrozole and 619 elected to cross
over. All patients provided informed written consent,
and all study protocols were approved by ethics
Kensler et al. Breast Cancer Research           (2019) 21:30 Page 2 of 11
committees at each study center and relevant health au-
thorities. BIG 1–98 is registered with ClinicalTrials.gov
(identifier NCT00004205).
Tissue markers
Tumor tissue biospecimens were collected retrospectively
in accordance with institutional guidelines and national
laws, with the financial support of Novartis. Tissue blocks
and/or slides were obtained for 6549 participants at the
International Breast Cancer Study Group (IBCSG) Central
Pathology Office in Milan, Italy. For 3784 participants,
two 1-mm-diameter cores per participant were obtained
from their formalin-fixed paraffin-embedded tumor speci-
mens and assembled into tissue microarrays (TMAs) in
Italy.
AR was centrally evaluated by immunohistochemistry
using the Dako AR441 antibody (1:200 dilution) at the
Dana-Farber/Harvard Cancer Center Specialized Histo-
pathology Services Core, Boston, MA, USA (TMA sec-
tioning and antibody staining) and Beth Israel Deaconess
Medical Center, Boston, MA, USA (scoring). The per-
centage of positive epithelial nuclei was estimated using
Definiens Tissue Studio automated imaging analysis soft-
ware version 4.4.2 (Munich, Germany). The average of
AR expression across the two cores was calculated for
each participant weighted by the number of detected nu-
clei. A cutoff of 1% expression or greater was used to de-
fine AR positivity in primary analyses. The Spearman
correlation between AR expression measured by Defini-
ens and three-tier manual pathologist scoring (< 1%, 1–
10%, > 10%) was 0.61 in a test TMA (n = 42 individuals).
Expression of ER, PR, and Ki67 was previously evaluated
on whole sections by immunohistochemistry (IHC) at
the IBCSG Central Pathology Office, as was the expres-
sion of HER2 by IHC and fluorescent in situ
hybridization [18–20]. ER and PR expression were
scored in increments of 5%, and Ki67 expression was
scored as a continuous measure. All tissue marker assays
were conducted blinded to participants’ treatment as-
signment and outcome. Spearman correlations were 0.24
between AR and ER expression, 0.16 between AR and
PR expression, and − 0.02 between AR and Ki67
expression.
Endpoints
The primary endpoint in this analysis was invasive breast
cancer-free interval (BCFI), which was defined in con-
cordance with STEEP criteria as the time from
randomization until the earliest of invasive local-regional
or distant recurrence or new invasive breast cancer in
the contralateral breast [26]. Disease-free survival (DFS)
was evaluated as a secondary endpoint and defined as
time from randomization until the earliest of invasive re-
currence, new invasive breast cancer in the contralateral
breast, second (non-breast) invasive malignancy, or
death from any cause.
Analytic population
A comparison of trial participants with and without as-
sessable AR expression is shown in Additional file 1:
Table S1. Of the 3784 participants whose specimens
were assembled on the TMAs, 82 participants did not
have ER expression assessed or were assessed as ER- by
central pathology review and were excluded, and 681
participants’ tissues were not assessable for AR staining
due to missing cores, non-intact or poor quality cores,
lack of tumor tissue in the core, or low cellularity, result-
ing in an analytic population of 3021 women (Fig. 1). Of
these, 1753 were assigned to either letrozole or tamoxi-
fen monotherapy. Prognostic analyses included partici-
pants from the monotherapy and mixed therapy arms
(n = 3021), while predictive analyses were limited to the
monotherapy population (n = 1753).
Statistical analysis
The associations between AR expression and patient and
tumor characteristics were evaluated using chi-square
tests for categorical variables and Wilcoxon rank sum
tests for continuous variables. The distribution of BCFI
and DFS were estimated using the Kaplan-Meier
method. The association between AR expression and
BCFI and DFS was evaluated both by the log-rank test
and using Cox proportional hazards models to estimate
hazard ratios (HRs) and 95% confidence intervals (95%
CIs). Models for this association were stratified by ran-
domized treatment assignment and receipt of chemo-
therapy, and were adjusted for participant, tumor, and
local treatment covariates. AR expression was evaluated
both as a dichotomous variable (≥1% versus < 1%) and
as a continuous variable. Restricted cubic splines were
used to evaluate potential non-linearity of the associ-
ation between AR expression and BCFI and DFS, though
tests for non-linearity were highly non-significant, and
AR expression was therefore modeled linearly as a con-
tinuous variable [27]. ER, PR, and Ki67 were included as
continuous linear measures in analyses.
AR was assessed as a predictive biomarker using Cox
proportional hazards models. In these analyses, partici-
pants who selectively crossed over from tamoxifen
monotherapy to letrozole monotherapy were censored at
the time of crossover. Heterogeneity of the treatment ef-
fect by dichotomous AR expression was assessed using a
likelihood ratio test for an AR-by-treatment interaction.
Subpopulation Treatment Effect Pattern Plot (STEPP)
analysis was used to evaluate heterogeneity of the treat-
ment effect across the continuum of AR expression [28,
29]. The STEPP approach entails calculating treatment
effects at 5 years post-randomization within sliding
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subpopulations defined by AR expression. Each subpop-
ulation contained approximately 200 patients and shared
approximately 100 patients with neighboring subpopula-
tions. STEPP was used to estimate 5-year cumulative in-
cidences of recurrence in a competing risk model and
hazard ratios. All analyses were conducted using R ver-
sion 3.5. All statistical tests were two-sided, and p < 0.05
was considered statistically significant.
For evaluation of AR as a prognostic marker, with a
sample size of 3021 women, 415 events, 82% AR+ tu-
mors, and setting α = 0.05 for a two-sided test, there was
80% power to detect an HR of 0.69 or lower for BCFI
[30]. To evaluate the AR-by-treatment interaction, with
1753 women in the monotherapy population, 236
events, 83% AR+ tumors in the letrozole arm, 80% AR+
tumors in the tamoxifen arm, and setting α = 0.05 for a
two-sided test, there was 80% power to detect a HR of
0.38 or lower for the AR-by-treatment product term for
BCFI [31].
Results
Distributions of participant, tumor, and treatment vari-
ables are shown in Table 1. Eighty-two percent of breast
cancers in this population were AR+ (≥ 1%) and the me-
dian AR expression was 12.5% (interquartile range [IQR]
2.1–30.6%). Women with AR+ breast cancers were more
likely to have smaller tumors (p < 0.001) and lower
histologic grade tumors (p < 0.001). Correspondingly,
women with AR+ cancers were more likely to have re-
ceived breast conserving surgery (p < 0.001), but receipt
of chemotherapy did not differ by AR status (p = 0.21).
AR+ tumors had higher ER and PR expression than AR−
tumors (both p < 0.001), but were less likely to overex-
press HER2 (p = 0.04). Ki67 expression did not signifi-
cantly differ between AR+ and AR− tumors (p = 0.07).
Over a median of 8.0 years follow-up (IQR 7.0–9.0
years) after randomization, a total of 415 BCFI events
(14% of analytic population) and 676 DFS events (22%)
occurred. Five-year BCFI was 93.1% (95% CI 92.1–
94.2%) among women with AR+ tumors and 90.5% (95%
CI 88.1–93.0%) among women with AR− tumors,
though differences in BCFI were not significant (p =
0.12, log-rank test) (Fig. 2). There was also no statisti-
cally significant difference in DFS by AR status (p = 0.35)
(Additional file 1: Fig. S1). After adjustment for partici-
pant, tumor, and treatment covariates, tumor AR expres-
sion was not associated with BCFI (HR = 1.07, 95% CI
0.83–1.38, p = 0.60) (Table 2), nor was it associated with
DFS (HR = 1.12, 95% CI 0.91–1.38, p = 0.27). When
evaluating AR expression continuously, each successive
10% increase in AR expression was not associated with
BCFI (HR = 1.02, 95% CI 0.97–1.08, p = 0.50).
In the Kaplan-Meier analysis in the monotherapy
population (n = 1753), BCFI was better for those
Fig. 1 Flow diagram of participant inclusion
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Table 1 Study population characteristics by tumor AR expression
Characteristic AR positivea
(n = 2475)
AR negativea
(n = 546)
P valueb
Treatment assignment, % –
Tamoxifen 21 21
Letrozole 22 18
Tamoxifen ➔ Letrozole 21 21
Letrozole ➔ Tamoxifen 21 20
Tamoxifen (2-arm period) 7 12
Letrozole (2-arm period) 8 10
Received chemotherapy, % 29 32 0.21
Local therapy, % < 0.001
Breast conserving surgery with radiation therapy 64 55
Breast conserving surgery without radiation therapy 4 5
Mastectomy with radiation therapy 12 18
Mastectomy without radiation therapy 20 22
Age at randomization, mean (SD) 62 (8) 62 (8) 0.10
Tumor size, % < 0.001
≤ 2 cm 67 54
> 2–< 5 cm 29 41
≥ 5 cm 3 4
Missing 1 1
Number of lymph nodes positive, % 0.15
0 63 58
1–3 26 30
4–9 7 8
10+ 3 3
Not evaluable 1 1
Tumor grade, % < 0.001
1 22 14
2 57 50
3 21 36
Missing 0 1
ER expression (%), median (25th–75th percentile) 95 (90–99) 90 (75–95) < 0.001
PR expression (%), median (25th–75th percentile) 70 (20–90) 50 (5–84) < 0.001
Missing, n 21 8
Ki67 expression (%), median (25th–75th percentile) 12 (6–18) 12 (6–20) 0.07
Missing, n 59 31
HER2 expression, % 0.04
Positive 5 8
Negative 95 92
Missing 0 0
aAR expression is defined as ≥ 1% positive, < 1% negative
bHypothesis testing for differences in distributions between AR+ and AR− tumors used chi-square and Wilcoxon rank sum tests for categorical and continuous
endpoints, respectively. Design variables (two- or four-arm randomization period and treatment assignment) were not compared. Individuals with missing data
were excluded when performing hypothesis tests for continuous variables
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assigned to letrozole than tamoxifen, regardless of tumor
AR expression (AR+ p = 0.02 from log-rank test; AR− p
= 0.04) (Fig. 3). Among those receiving letrozole mono-
therapy, 5-year BCFI was 94.7% (95% CI 93.1–96.4%) for
women with AR+ tumors and 95.2% (95% CI 91.8–
98.7%) for women with AR− tumors, while among those
receiving tamoxifen, 5-year BCFI was 90.7% (95% CI
88.4–93.0%) for women with AR+ tumors and 85.7%
(95% CI 80.5–91.2%) for women with AR− tumors. Pat-
terns were similar for DFS (Additional file 1: Fig. S2).
In multivariable-adjusted Cox models, participants
assigned to letrozole monotherapy experienced signifi-
cantly better BCFI compared to participants assigned to
tamoxifen monotherapy (HR[Let.:Tam.] = 0.57, 95% CI
0.44–0.75, p < 0.001), as was found in the total trial popu-
lation (Table 3). The treatment effect for BCFI was sug-
gestively stronger among AR− breast cancers
(HR[Let.:Tam.] = 0.39, 95% CI 0.21–0.72, p = 0.002) than
among AR+ breast cancers (HR[Let.:Tam.] = 0.63, 95% CI
0.47–0.85, p = 0.003), though this difference was not sta-
tistically significant (p-heterogeneity = 0.16). Among those
assigned to letrozole monotherapy, AR expression was as-
sociated with non-significantly worse BCFI (HR[AR+:AR
−] = 1.52, 95% CI 0.88–2.62, p = 0.13), while among those
assigned to tamoxifen, AR expression was not associated
with BCFI (HR[AR+:AR−] = 0.94, 95% CI 0.62–1.43, p =
0.77). Similar trends were observed for DFS.
STEPP analysis of the letrozole versus tamoxifen treat-
ment effect across the continuum of AR expression indi-
cated general superiority of letrozole monotherapy,
irrespective of AR expression (Fig. 4). Five-year BCFI
was generally worse for those assigned to tamoxifen
monotherapy within all subpopulations of AR expres-
sion. Correspondingly, absolute and ratio measures of
the treatment effect at 5 years generally favored letrozole
monotherapy. There were no systematic trends in the
magnitude of these effects across the continuum of AR
expression.
Discussion
We evaluated AR as a prognostic and predictive marker
among 3021 postmenopausal participants of the BIG 1–
Fig. 2 Kaplan-Meier estimate of breast cancer-free interval by tumor AR expression. AR expression is defined as ≥ 1% positive, < 1% negative. P
value from log-rank test is 0.12
Table 2 Multivariable-adjusted hazard ratios (95% CI) for breast
cancer-free interval and disease-free survival by tumor AR
expression
AR+ vs. AR− 10% increase
Individuals Events HR (95% CI) HR (95% CI)
Breast cancer-free interval
Model 1a 3021 415 0.84 (0.66–1.07) 0.97 (0.92–1.02)
p = 0.16 p = 0.26
Model 2b 2907 398 1.07 (0.83–1.39) 1.02 (0.97–1.08)
p = 0.60 p = 0.50
Disease-free survival
Model 1 3021 676 0.95 (0.78–1.15) 0.97 (0.93–1.01)
p = 0.58 p = 0.19
Model 2 2907 650 1.12 (0.91–1.38) 1.01 (0.96–1.05)
p = 0.27 p = 0.77
Hazard ratios (HRs) compare AR+ (≥ 1%) to AR− (< 1%) cancers or represent
association per each successive 10% increase in AR expression
aModel 1: Stratified by treatment assignment and receipt of chemotherapy,
and adjusted for age at randomization
bModel 2: Model 1 + adjusted for tumor size, lymph node involvement, local
therapy, ER, PR, HER2, and Ki67 expression
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98 trial with early stage ER+ breast cancer. Tumor AR
expression was associated with more favorable tumor
features including smaller size, lower grade, lower likeli-
hood of lymph node involvement. After adjusting for pa-
tient, tumor, and treatment factors, AR expression was
not associated with breast cancer prognosis in this popu-
lation. Moreover, AR expression was not a significant
predictor of therapeutic response, though, suggestively,
the superiority of monotherapy with letrozole relative to
tamoxifen was more pronounced among women with
AR−/ER+ cancers. These findings were similar for a di-
chotomous measure of AR expression (cut at 1%) and
when evaluating the continuum of AR expression.
The androgen receptor is an emerging prognostic
marker for breast cancer, with a recent meta-analysis by
Bozovic-Spasojevic et al. of 13 studies (n = 5648 patients)
finding tumor AR expression to be associated with im-
proved DFS in the multivariate analysis (HR = 0.46, 95%
CI 0.37–0.58) [12]. This association may mask differen-
tial effects of AR signaling in ER+ and ER− breast can-
cers [8–10]. In vitro models of AR+/ER− breast cancers
have indicated that AR signaling can drive cell prolifera-
tion in these cancers [11, 32]. However, there is incon-
sistent evidence for a deleterious effect of AR signaling
in ER− breast cancers at a population level, with epide-
miologic studies finding harmful [33–35], beneficial [36,
Fig. 3 Kaplan-Meier estimate of breast cancer-free interval by cross-classified AR expression and treatment in monotherapy population. AR
expression is defined as ≥ 1% positive, < 1% negative
Table 3 Multivariable analysis of letrozole versus tamoxifen treatment effect by tumor AR expression
All monotherapy AR+ AR− P-
HetcIndividuals Events HR (95% CI) HR (95% CI) HR (95% CI)
Breast cancer-free interval
Model 1a 1753 236 0.67 (0.52–0.87) 0.73 (0.55–0.98) 0.49 (0.27–0.87) 0.22
p = 0.003 p = 0.03 p = 0.02
Model 2b 1697 227 0.57 (0.44–0.75) 0.63 (0.47–0.85) 0.39 (0.21–0.72) 0.16
p < 0.001 p = 0.003 p = 0.002
Disease-free survival
Model 1 1753 401 0.75 (0.62–0.92) 0.80 (0.64–0.99) 0.61 (0.39–0.94) 0.27
p = 0.005 p = 0.04 p = 0.03
Model 2 1697 388 0.69 (0.56–0.84) 0.73 (0.59–0.92) 0.52 (0.33–0.83) 0.19
p < 0.001 p = 0.008 p = 0.005
AR expression is defined as ≥ 1% positive, < 1% negative. This analysis is restricted to 1753 patients who received letrozole or tamoxifen monotherapy
aModel 1: Stratified by receipt of chemotherapy and adjusted for age at randomization, AR expression (all monotherapy analysis only)
bModel 2: Model 1 + adjusted for tumor size, lymph node involvement, local therapy, ER, PR, HER2, and Ki67 expression
cP value is from test of heterogeneity of treatment effect in AR+ and AR− cancers
Kensler et al. Breast Cancer Research           (2019) 21:30 Page 7 of 11
37], and null [5, 14, 38, 39] associations. AR has also
emerged as a promising therapeutic target, particularly
for AR+ triple-negative breast cancers [40]. Epidemio-
logic evidence generally supports an inverse association
between AR expression and breast cancer mortality for
ER+ cancers, though we found no association in our
study. The Bozovic-Spasojevic et al. meta-analysis found
improved DFS associated with AR expression in ER+
breast cancers (multivariate HR = 0.40, 95% CI 0.31–
0.52, n = 1571 patients) [12]. Prior meta-analyses have
also found inverse associations [41–43], though the
addition of our study to this body of literature would at-
tenuate overall evidence for an association. The inverse
association observed in the majority of epidemiologic
studies aligns with results from experimental models,
where higher levels of AR were correlated with a lower
rate of proliferation in MCF7 cells [44]. Treatment with
enzalutamide, an AR antagonist, abrogated androgen-
driven proliferation in MCF7 cells and xenographs [22].
However, blockade of androgen synthesis with abirater-
one acetate plus prednisone did not improve
progression-free survival relative to treatment with exe-
mestane in a phase II trial among 297 patients with ER+
metastatic breast cancer [45]. Cistrome analyses have
found that the AR and ER may compete to occupy estro-
gen response elements, with bound AR-reducing cellular
proliferation [13, 46]. Alternatively, AR may have unique
binding sites at ER target genes through which it could
directly inhibit transcription or it may indirectly inhibit
transcription through competition for co-regulators [10].
In contrast to our own study, several prior observa-
tional studies have found AR to be a predictive marker
for endocrine therapy response in ER+ breast cancers.
However, this evidence is conflicting and primarily relies
on univariate analyses. In the largest study to date (n =
938), AR expression was associated with improved
disease-specific survival for women receiving endocrine
therapy and chemotherapy, but not endocrine therapy
alone [47]. In contrast, in a separate cohort of 119
women with ER+ breast cancer, endocrine therapy alone
was associated with better outcomes [21]. There is also
evidence that AR signaling could predict endocrine ther-
apy resistance. An AR:ER ratio ≥ 2 was associated with
an increased rate of tamoxifen failure in a cohort of 192
women with ER+ breast cancer, though these tumors
may be more receptive to treatment with AR-antagonists
Fig. 4 Subpopulation Treatment Effect Patten Plot (STEPP) analysis of
the letrozole versus tamoxifen treatment effect. Treatment effect is
defined as the 5-year BCFI in the monotherapy population (n = 1753).
Plots show treatment effects in subpopulations denoted by median AR
expression on the x-axis. Treatment effects are shown as a 5-year
cumulative incidences (%), b 5-year cumulative incidence differences
(95% CI) [Let. – Tam.], and c hazard ratios (95% CI) [Let.:Tam.]
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[22]. Likewise, an effect of AR expression on tamoxifen
resistance has been observed in in vitro models, poten-
tially mediated through activation of epidermal growth
factor receptor signaling pathways [48, 49]. However, a
study among 590 women found that AR did not predict
tamoxifen response in AR+/ER+ cancers, though it did
suggest a benefit to tamoxifen treatment for AR+/ER−
cancers [33]. Finally, a recent study conducted among
102 patients receiving endocrine therapies for ER+
breast cancers also found no association between AR ex-
pression and treatment response [50].
We found no association between tumor AR expres-
sion and response to tamoxifen among postmenopausal
women with ER+ breast cancers. We had postulated that
AR expression would lead to enhanced response to
letrozole via increased AR activity that would dampen
ER signaling; however, our findings do not support this
hypothesis. We observed that AR expression was sug-
gestively but non-significantly associated with a higher
rate of recurrence among those assigned to receive letro-
zole. Despite the non-significantly lower efficacy of letro-
zole in AR−/ER+ breast cancers, survival outcomes
among those receiving letrozole monotherapy were su-
perior to those among individuals receiving tamoxifen
regardless of tumor AR expression. As such, we found
no evidence that tumor AR expression should be consid-
ered in the selection of adjuvant endocrine therapy.
This study represents the largest and most compre-
hensive evaluation of AR expression as a predictor of
endocrine therapy response to date. In particular, the
randomized design allows for better assessment of thera-
peutic effects relative to the observational designs used
in prior studies. This setting also allows for careful ad-
justment for tumor features that influence prognosis.
However, lifestyle factors that influence breast cancer
prognosis, such as body mass index, were not measured
in the BIG 1–98 population. Additional strengths of this
analysis include the use of central pathology assessment
of AR and other tumor markers, as well as the evalu-
ation of a continuous measure of AR expression. The
optimal cut-point that maximizes clinical utility of AR
has not yet been identified, though recent studies sug-
gest that it may be greater than 1% or 10%—the most
common cut-points used to date [7, 13, 51, 52]. Ricciar-
delli and colleagues found that neither the 1% or 10%
cut-points were robustly prognostic, while a cut-point of
78% maximized sensitivity and specificity for predicting
breast cancer survival [7]. Likewise, multiple antibodies
have been used to measure AR protein expression, but
the AR441 antibody has been used in the majority of
studies evaluating AR as a prognostic marker for breast
cancer [7]. AR expression was only assessable for a sub-
set of the BIG 1–98 trial population. Patients who en-
rolled early into the trial were less likely to have tumor
tissue submitted for tumor marker analyses. This con-
tributes to some imbalances in tumor characteristics be-
tween the populations with and without assessable AR
expression. BCFI is superior in the AR analytic popula-
tion than in the total trial population, and the letrozole
versus tamoxifen treatment effect is also stronger in this
analytic population [17]. An additional limitation of our
study is that due to large differences in the distributions
of AR and ER expression in our data, we were unable to
rigorously assess the prognostic and predictive value of
previously identified cut-points, 0.87 and 2.0, of the
AR:ER ratio [7, 22]. Finally, these findings are pertinent
to the population of postmenopausal women with early
stage ER+ breast cancer receiving letrozole and tamoxi-
fen and may not necessarily reflect the influence of AR
expression on the efficacy of other endocrine therapies.
Conclusions
AR protein expression was not associated with prognosis
in this population of postmenopausal women with early
stage ER+ breast cancer, nor was it predictive of re-
sponse to tamoxifen or letrozole. These findings do not
support consideration of tumor AR expression in the
choice of initial adjuvant endocrine therapy.
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